This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Viral Vectors in Cell & Gene Therapies (& aspects of mRNA Therapeutics)

Early Registration Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Starting Course not running
Starting Course not running
Course has been canceled please see link below to visit our other courses taking place in 2022

Course Overview

Viral vectors are the buzz word in the world of gene and gene-modified cell therapies – but have you ever understood why? 

Viral vector technology is fundamental for the successful engineering and delivery of life-saving gene and gene-modified cell therapies, yet mishandling or inappropriate vector selection could sabotage your therapy and compromise patient safety.

Over 7 sessions, this course will not only explore the underlying virology, but familiarize you with the best practices to ensure you are using the most appropriate vector for your product.

You will learn: how vectors are engineered; how gene size and transfection efficiency influence vector selection; as well as, how to contrast purification requirements and techniques between vectors used for gene and gene-modified cell therapies.

What will you learn?

Current and Emerging Therapies

From vaccines and antibody therapeutics to cell & gene technologies – gain insight into the latest emerging trends, their applications and future potential.

Cell & Gene Therapy Introduction

Learn about the key definitions, science and technologies behind today's growing cell & gene therapy market.

Underlying virology

Understand why viruses are used to engineer and deliver gene-modified cell and gene therapies


Familiarize yourself with how viral vectors are engineered, and how this translates into purification techniques

Viral vector selection

Consider important factors for selecting the most appropriate vector for your product, including gene size and transfection efficiency

Purification requirements

Understand how purification requirements, such as host cell DNA and residual empty capsids, are influenced by vector manufacture and end-use application, compare how these requirements differ between gene therapy and gene-modified cell therapies

Purification techniques

Appreciate that specific purification techniques are influenced by specific purification requirements of your product, then consider the different tests available to assess purification including qPCR, ELISA and TC1D50

Who is this course for?

This course is directly applicable to people working on the manufacturing of gene therapies and gene-modified cellular therapies. Relevant departments will include:

  • Gene Therapy Process Development
  • Cell Therapy Engineering
  • Cell Therapy Process Development
  • Quality Control/Assurance
  • Regulatory Affairs
  • Final Release Testing